<https://helda.helsinki.fi>

Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF-blocking agents

Molander, Pauliina

2017

Molander , P , Farkkila , M , Kemppainen , H , Blomster , T , Jussila , A , Mustonen , H & Sipponen , T 2017 , ' Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF-blocking agents ' , Scandinavian Journal of Gastroenterology , vol. 52 , no. 3 , pp. 284-290 . <https://doi.org/10.1080/00365521.2016.1250942>

<http://hdl.handle.net/10138/311875>

<https://doi.org/10.1080/00365521.2016.1250942>

unspecified

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

LONG-TERM OUTCOME OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH DEEP REMISSION AFTER DISCONTINUATION OF TNF α -BLOCKING AGENTS

Journal:	<i>Scandinavian Journal of Gastroenterology</i>
Manuscript ID	Draft
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Molander, Pauliina; Helsinki University Central Hospital and University of Helsinki, Peijas Hospital, Department of Gastroenterology Färkkilä, Martti; Helsinki University Central Hospital and University of Helsinki, Department of Gastroenterology Kemppainen, Helena; Turku University Central Hospital, Department of Gastroenterology Blomster, Timo; Oulu University Central Hospital, Department of Gastroenterology Jussila, Airi; Tampereen yliopistollinen sairaala, Department of Gastroenterology and Alimentary Tract Surgery Mustonen, Harri; Helsinki University Central Hospital and University of Helsinki, Department of Surgery Sipponen, Taina; Helsinki University Central Hospital and University of Helsinki, Department of Gastroenterology
Keyword:	Crohn's disease, Ulcerative colitis, Relapse, Withdrawal, TNF α -antagonist, Infliximab, Adalimumab

SCHOLARONE™
Manuscripts

**LONG-TERM OUTCOME OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH
DEEP REMISSION AFTER DISCONTINUATION OF TNF α -BLOCKING AGENTS**

Authors:

Pauliina Molander ¹, Martti Färkkilä ¹, Helena Kemppainen ², Timo Blomster ³, Airi Jussila
⁴, Harri Mustonen ⁵, Taina Sipponen ¹

¹ Department of Gastroenterology, Helsinki University Central Hospital and University of
Helsinki, Helsinki, Finland

² Turku University Central Hospital, Turku, Finland.

³ Oulu University Central Hospital, Oulu, Finland.

⁴ Department of Gastroenterology and Alimentary Tract Surgery, Tampere University
Hospital, Tampere, Finland.

⁵ Department of Surgery, Helsinki University Central Hospital and University of Helsinki,
Helsinki, Finland.

Corresponding author:

Pauliina Molander, M.D. PhD

Gastroenterology, Helsinki University Central Hospital, Peijas Hospital, Vantaa, Finland.

P.O.Box 900, FIN-00029, HUS, Finland.

e-mail: pauliina.molander@hus.fi.

Telephone number: +358 9 4711

Key words:

Crohn's disease; ulcerative colitis; relapse; stopping; TNF α -antagonist; infliximab; adalimumab

ABSTRACT:**Background:**

Little data exist on the long-term prognosis of patients with inflammatory bowel disease (IBD) after stopping TNF α - blocking therapy in deep remission. Existing data indicate that approximately 50% of patients on combination therapy who discontinued TNF α - blockers are still in remission 24 months later. The aims of this follow-up analysis was to evaluate the long-term remission rate after cessation of TNF α -blocking therapy, the predicting factors of a relapse and the response to restarting TNF α blockers.

Methods:

The first follow-up data of 51 IBD patients (17 Crohn's disease [CD], 30 ulcerative colitis [UC] and 4 inflammatory bowel disease type unclassified [IBDU]) in deep remission at the time of cessation of TNF α -blocking therapy have been published earlier. The long-term data was collected retrospectively after the first follow-up year to evaluate the remission rate and risk factors for the relapse after a median of 36 months.

Results:

After the first relapse-free year, 14 out of the remaining 34 IBD patients relapsed (41%; 5/12 [42%] CD and 9/22 [41%] UC/IBDU). Univariate analysis indicated no associations with any

predictive factors. Re-treatment was effective in 90% (26/29) of patients.

Conclusion:

Of IBD patients in deep remission at the time of cessation of TNF α -blocking therapy, up to 60% experience a clinical or endoscopic relapse after a median follow-up time of 36 months (95% CI 31-41 months). No individual risk factors predicting relapse could be identified. However, the initial response to a restart of TNF α -blockers seems to be effective and well tolerated.

INTRODUCTION

The chronic nature of inflammatory bowel disease (IBD) and lack of recommendations for cessation of TNF α -blocking therapy may lead to long-term maintenance therapy with TNF α blockers as early treatment recommendations have become more widely accepted. With patients achieving remission, the potential severe side effects (i.e. infections, acute infusion reactions, delayed hypersensitivity reactions, risk of neoplasia, and safety issues during pregnancy) and economic issues prompt the questions on cessation of TNF α -blocking therapy.^{1,2,3,4} In addition, it is nowise certain that the benefits of TNF α -blocking agents are permanent in the long run.

Several studies show that the overall risk of relapse after discontinuation of TNF α -blocking agents is 44% for Crohn's disease (CD, follow-up range of 6-125 months) and 38% for ulcerative colitis (UC, follow-up range of 6-24 months).^{5,6,7,8,9,10,11,12,13,14,15} The relapse risk seems to be lower in IBD patients who are in deep remission (clinical, biological and endoscopic remission) at the time of cessation of TNF α -blocking therapy

1
2
3 compared to those in clinical remission only.⁹ Available data are insufficient for giving
4
5 strong recommendations on at what point safely cease TNF α -blocking therapy. Therefore
6
7 the decisions should be based on assessment of the patient's individual risks and benefits.
8
9
10 In CD several factors have been investigated to identify patients who are more likely to
11
12 achieve long-term remission after discontinuation of TNF α -blocking agents. The factors
13
14 that have been associated with a higher risk of relapse are younger age, smoking, longer
15
16 disease duration, fistulising phenotype, perianal disease, short duration of remission,
17
18 previous surgical operation, endoscopically active disease, ileocolonic disease at
19
20 diagnosis and previous TNF α -blocking therapy, high markers of inflammation and high
21
22 infliximab trough level. On the other hand, mucosal healing, colonic CD, a shorter interval
23
24 between disease diagnosis and starting anti-TNF, concomitant immunosuppressive therapy
25
26 and absence of antibodies to TNF α -blocking agents seem to decrease the risk of relapse
27
28 after discontinuation of TNF α -blocking agents.^{6,7,10,12,13, 14,15,16} A study by Waught
29
30 and co-workers shows that 35% of the CD patients with a follow-up for nearly seven years
31
32 after discontinuation of therapy remained in sustained clinical remission. No specific factor
33
34 was associated with the duration of CD remission.¹⁷ In patients receiving TNF α -blocking
35
36 agents for the prevention of post-operative CD recurrence, the risk of relapse after
37
38 discontinuation is very high (>75%) and the ceasing decision should be based on very
39
40 good reasons.¹⁸ Importantly, restarting of TNF α -blocking therapy for those who relapsed
41
42 after stopping treatment seems to be effective and well-tolerated.^{5,6,9,10,12}
43
44
45
46
47
48
49
50

51 We have earlier published a prospectively collected 12-month data of cessation of TNF α -
52
53 blocking therapy in IBD-patients with deep remission.⁹ The aim of this study was to
54
55 evaluate the long-term relapse rate after the first year of follow-up and the predictive
56
57
58
59
60

factors for relapse in this study population, as well as the response rate to TNF α -blocking agents after the restart of medication in the case of relapse.

MATERIALS AND METHODS

Patients and study design

All 51 IBD patients in this follow-up analysis were primarily recruited in a prospective multicenter study which was carried out at nine gastroenterological centers in Finland during the period from February 2010 to June 2013.⁹ At the time of inclusion all patients were in deep remission (i.e. clinical, endoscopic and faecal calprotectin -based [FC <100 μ g/g] remission). After the primary study, one UC patient was dropped from the follow-up due to no available data on a patients' report. Clinical notes of all enrolled patients were retrospectively reviewed for this long-term follow-up. All patients had an established IBD diagnosis, had received TNF α -blocking maintenance therapy for a minimum of one year (the median duration of infliximab [IFX] therapy was 13 [n = 46, range 11-77] months and adalimumab [ADA] therapy 27 [n = 5, range 16-36] months), had been in corticosteroid-free remission over a 6-months period prior to the inclusion, were in clinical, FC-based (FC <100 μ g/g) and endoscopic remission at the time of inclusion. Due to its small size, the subgroup IBDU of four patients was combined with the UC group.

Given the retrospective design of this study, clinical disease activity was assessed by the physicians' global assessment (asymptomatic patients vs. symptomatic patients indicating active IBD) in patients relapsing after the first year of follow-up and 12 months after the restart of TNF α -blocking therapy. At relapse endoscopic findings were scored, as in our earlier study ⁹, according to the SES-CD¹⁹ in CD and endoscopic Mayo score in UC and

IBDU.²⁰ An SES-CD of 3-6 was defined as mildly active disease, 7-15 as moderately active disease, and ≥ 16 as severely active disease.²¹ Endoscopic Mayo subscore of ≥ 2 defined active disease.²²

In a case of a clinical and/or endoscopic relapse after the first year of follow-up, TNF α -blocking therapy was restarted at the same dose and frequency as prior to withdrawal in exception of two patients, whose relapses were treated with oral corticosteroids or mesalazine. Ileocolonoscopy was performed 12 months after the restart of TNF α -blocking therapy in exception of four patients with normal fecal calprotectin levels. Endoscopic activity was defined as mild, moderate, or severe by an experienced gastroenterologist.

Fecal calprotectin assays

FC was measured using the quantitative enzyme immunoassay (the CALPRO® Calprotectin ELISA Test [ALP; Calpro AS, Lysaker, Norway]). The values quoted as normal were $< 100 \mu\text{g/g}$.²³

Statistics

The Statistical Package for the Social Sciences (SPSS version 23) for Windows software (SPSS, Chicago, IL, USA) was used for data analyses. Fisher's exact test was used to determine differences in binary variables. The significance was set at $p < 0.05$ and two-tailed tests were used. Kaplan-Meier survival analysis was employed in estimation of relapse-free survival rates, and the log-rank test was used to determine the differences between the groups. The Cox regression of proportional hazards was used to calculate univariate hazard ratios for categorical and continuous variables. The results were given as percentages, as median and range, or as mean and standard deviation (SD).

Ethical statement

The study protocol and all documents of the prior prospective multicenter study were approved by the ethics committee at Helsinki University Hospital and at each participating university central hospital. Because this follow-up study was a retrospective reviewing of patients' medical records, no separate application for ethics committee was needed.

RESULTS

The baseline characteristics are described in Table 1. As established in earlier publication, during the first 12-month follow-up, up to 33% of patients (5/17 [29%] CD and 12/34 [35%] UC/IBDU) in deep remission relapsed.¹⁰ After the first relapse-free year, 14 of the remaining 34 IBD patients relapsed (40%; 5/12 [42%] CD and 9/22 [41%] UC/IBDU) during median follow-up period of 36 months (1-69; in CD 38 months [3-68] and in UC 35 months [1-69]). Of the 14 relapsed patients, endoscopic data were available on 13 at the time of a relapse. Out of five relapsed CD patients, one experienced a severe clinical relapse without endoscopic documentation, two experienced both clinical and endoscopic relapse (SES-CD 8 and 10) and two experienced moderate endoscopic relapse without clinical symptoms mean (SES-CD 7 and 9). All UC patients experienced both clinical and endoscopic relapse (mean endoscopic Mayo score 2 [2-3]).

The time-to-relapse curves of all patients are shown in Figure 1. No significant difference was found in the relapse rate between CD and UC/IBDU, $p = 0.919$.

The risk factors for relapse

Based on univariate analysis (Cox model) risk factors such as diagnosis, gender, disease duration, localization, behavior, smoking, family history, previous surgery, the TNF α -blocking agents used, concomitant medications or duration of the used TNF α -blocking agents were not associated with the risk of relapse, Table 2.

Restarting TNF α -blocking therapy

The response after restarting TNF α -blocking therapy was evaluated in all 29 of 51 IBD patients, Figure 2. The median time of follow-up after retreatment with TNF α -blocking agents was 12 (range 3-19) months. One relapsed UC patient was treated with corticosteroid and another with mesalazine instead of TNF α -blocking agents. After the restarting TNF α -blocking therapy, all except one UC patient achieved clinical remission or response at three months. During the follow-up period, three patients were operated on: one UC patient underwent colectomy less than two months after the restart of TNF α -blocking therapy due to nonresponse and another UC patient underwent colectomy after one year of TNF α -blocking therapy due to loss of response. Furthermore, one CD patient underwent ileo-cecal resection after one year of TNF α -blocking therapy due to a symptomatic stricture. After a restart of IFX, two UC patients experienced an infusion reaction (one during the second IFX infusion without anti-drug antibody measurement and the other one six months after restarting developing anti-drug antibodies) and were treated with another TNF α -blocking agent. In addition, despite a combination therapy with thiopurins, three patients (one CD and two UC patient) developed low concentrations of anti-drug antibodies, but achieved a clinical response by dose escalation (one CD and one UC patient) or by switching to another TNF α -blocking agent (one UC patient). Twelve months after the restart of TNF α -blocking therapy 20 patients (39%; 8 CD, 12 UC) were still in clinical remission. Six patients with CD and 11 patients with UC underwent a 12-

month follow-up ileocolonoscopy, showing either endoscopic remission (4 CD, 9 UC) or mild activity (3 CD, 2 UC). The remaining three patients (2 CD, 1 UC) had normal calprotectin levels serving as surrogate markers to endoscopic remission.

DISCUSSION

It is well known that TNF α -blocking therapy is effective in inducing and maintaining remission in IBD patients with moderate to severe CD and UC and therefore, for responders the long-term maintenance therapy is recommended.^{24,25} However, life-long TNF α -blocking therapy in IBD patients in clinical remission or in deep remission is still questioned, since early treatment with an immunomodulator and/or TNF α -blocking agonist are nowadays recommended ²⁶ and long-term safety issues are still debated.

According to this follow-up study almost 60% of patients relapsed after a median follow-up time of 36 months. No statistically significant difference in the relapse rates between CD and UC was found. Several studies, mainly with CD patients, have been published on the duration of remission after a discontinuation of TNF α -blocking therapy, and only few of these studies have assessed endoscopic activity during a long-term follow-up. It is interesting to note, that across all studies reporting on anti-TNF withdrawal of adult IBD patients in clinical remission, despite heterogeneous study designs and patient populations, the one and two -year relapse rates were reasonably consistent ranging from 21-39% and from 37%-56% respectively.^{6,7,8,9,10,11,12,13} These findings are in line with our results despite the fact that no baseline endoscopic remission was required in the majority of those earlier studies. However, recently published long-term data of the patients included in the STORI trial seem to indicate poorer remission rates after cessation

of IFX for sustained remission: the vast majority of CD patients (85%) had to restart the treatment over the course of time.²⁷ The longest follow-up periods reported are 10 years in CD¹⁴ and 7 years in UC.¹⁵ Cumulative relapse rates in all studies rise over time.

Cessation of TNF α -blocking therapy may be considered for patients with a low relapse risk. The relapse risk may be minimized using predictors that identify those at a clinically meaningful risk of relapse. Achieving deep remission is currently considered to be the most important protective factor in disease relapse after TNF α -blocking therapy withdrawal.²⁸ Many of the risk factors shown in previous studies have been associated with incomplete remission with ongoing inflammatory disease activity at the time of discontinuation. It seems likely that not only the disease activity at the time of cessation of TNF α -blocking therapy but also previous disease history may have an impact on the risk of disease relapse following TNF α -blocking therapy withdrawal. Factors affecting the duration of a clinical remission after discontinuing anti-TNF therapy remain questionable even today. Moreover, it is very likely that patients' initial response to TNF α -blocking therapy and tendency to maintain sustained remission after therapy withdrawal is based on a patient-unique genetic type of IBD disease.^{29,30} Future studies are needed to analyze the correlation of patients' genotype and the duration of remission after discontinued TNF α -blocking therapy. As clear and widely accepted recommendations for discontinuing TNF α -blocking therapy are lacking, it has been stated that biological therapy should not be stopped in patients who have undergone multiple previous operations, demonstrated intolerance to conventional drugs or in whom the disease is difficult to control.³¹ A multidisciplinary European expert panel (European Panel on the Appropriateness of Crohn's Disease Treatment II, EPACT-II) considered discontinuing TNF α -blocking therapy to be appropriate after four years, but also after two years if the

1
2
3 patient was in deep remission.³² The results of our previous study suggested that
4
5 withdrawal of TNF α -blocking therapy after one year could be possible in IBD patients with
6
7 deep remission as the duration of TNF α -blocking therapy did not influence the relapse risk
8
9 over time.⁹ Nevertheless, considering the possible adverse events after stopping TNF α -
10
11 blocking therapy, withdrawal should be considered carefully and discussed with the
12
13 patient.
14
15

16
17
18
19 After a drug-holiday, the risk of immunization resulting in infusion reactions and loss of
20
21 response should be considered.^{33,34} Unfortunately, most of the studies report only short-
22
23 term outcomes and therefore more evidence is needed to demonstrate the real efficacy
24
25 and safety of re-treatment. The studies including longer follow-up periods have reported
26
27 remission rates from 80 to 92%.^{7,8} These findings are in line with our study, all but one of
28
29 the patients achieved clinical remission or response at three months and the remission
30
31 rate at one year was considerably high (97%). However, the risk of developing anti-drug
32
33 antibodies may lead to infusion reaction and loss of response followed by severe
34
35 problems. In our study, three patients underwent surgery due to no response to re-
36
37 treatment and five patients developed either anti-drug antibodies and/or experienced an
38
39 infusion reaction. Taking this into account, withdrawal of TNF α -blocking therapy needs to
40
41 be considered carefully.
42
43
44
45

46
47
48 Our study has some limitations. The patient group is limited and heterogeneous and the
49
50 number of patients in the subgroups low. Moreover, cut-off levels used for endoscopic
51
52 remission (SES-CD score and endoscopic Mayo score) may have allowed mild
53
54 endoscopic activity at baseline and also during the follow-up. However, we consider that
55
56 low baseline FC value as another criterion of remission ruled out patients with notable
57
58
59
60

inflammatory activity.³⁵ Furthermore, clinical and endoscopic data after one year of stopping TNF α -blocking therapy was not collected for the study purpose. Therefore clinical scores were not available for all patients at the time of relapse and clinical and endoscopic scores were not available after the restart of TNF α -blocking therapy for all patients. However, the strength of this study is a long term surveillance after cessation of TNF α -blocking therapy in a clinical setting and endoscopic verification of a relapse.

The long-term follow-up demonstrates a fairly high relapse rate after cessation of TNF α -blocking therapy among IBD patients in deep remission. However, two out of five patients seem to remain in sustained clinical remission after cessation of TNF α -blocking therapy, but selecting these patients among potential relapsers is challenging. In relapsers, the response to a restart of TNF α antagonists seems to be effective and fairly well tolerated, even if the formation of anti-drug antibodies may result in to dose escalation or a change of TNF α -blocking agent. Therefore withdrawal of TNF α -blocking therapy should be considered carefully on individual bases.

DISCLOSURES

Statement of authorship: study design (PM, MF, TS), data collection (PM, HK, TB, AJ), statistical analysis (PM, HM), drafting the manuscript (PM, TS), final reading and approval of the manuscript (all authors).

PM received lecture fees from Abbvie, Ferring and MSD and consulting fees from Abbvie, MSD and Takeda. MF received consulting fees from MSD, Abbvie, Janssen, Orion Pharma, Medivir and Roche, and lecture fees from MSD, Abbvie, Bayer, Janssen and

Tillots Pharma. TB received lecture fees from Abbvie and Tillotts Pharma and consulting fees from Abbvie. AJ received lecture fees from Abbvie, Ferring, MSD, Takeda and Tillotts Pharma and consulting fees from Abbvie, Hospira, MSD, Takeda and Tillotts Pharma. TS received lecture fees from Abbvie, AstraZeneca, Ferring, Medac, MSD, Pfizer, Tillots Pharma and Vifor Pharma and consulting fees from Hospira, Takeda, MSD and Tillotts Pharma. HK and HM declare no conflicts of interest.

REFERENCES

1. Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P, Shand AG, Penman ID, Palmer KR, Wilson DC, Arnott ID, Satsangi J. The safety profile of anti-tumor necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-year follow-up. *Aliment Pharmacol Ther* 2009;29:286–97.

2. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. *Clin Gastroenterol Hepatol* 2009;7:874–81.

3. Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. *Expert Rev Clin Immunol* 2010;6:621–31.

4. Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. *Inflamm Bowel Dis* 2011;17:1846–54.

- 1
2
3 5. Molnar T, Lakatos PL, Farkas K, Nagy F, Szepes Z, Miheller P, Horváth G, Papp M,
4
5 Palatka K, Nyári T, Bálint A, Lőrinczy K, Wittmann T. Predictors of relapse in patients with
6
7 Crohn's disease in remission after 1 year of biological therapy. *Aliment Pharmacol Ther*
8
9 2013;37:225-33.
10
- 11 6. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL,
12
13 Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud
14
15 G, Piver E, Colombel JF, Lemann M; Groupe D'etudes Thérapeutiques Des Affections
16
17 Inflammatoires Digestives. Maintenance of remission among patients with Crohn's disease
18
19 on anti-metabolite therapy after infliximab therapy is stopped. *Gastroenterology*
20
21 2012;142:63–70.
22
- 23 7. Brooks AJ, Sebastian S, Cross SS, Robinson K, Warren L, Wright A, Marsh AM, Tsai H,
24
25 Majeed F, McAlindon ME, Preston C, Hamlin PJ, Lobo AJ. Outcome of elective withdrawal
26
27 of antitumour necrosis factor- α therapy in patients with Crohn's disease in established
28
29 remission. *J Crohns Colitis* 2015; Epub ahead of print
30
31
- 32 8. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard, Thomsen O.
33
34 Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in
35
36 clinical remission: an observational Danish single center study. *Scand J Gastroenterol*
37
38 2012;47:518–27.
39
40
- 41 9. Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A,
42
43 Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J,
44
45 Kolho KL, Mustonen H, Sipponen T. Outcome after discontinuation of TNF α -blocking
46
47 therapy in patients with inflammatory bowel disease in deep remission. *Inflamm Bowel Dis*
48
49 2014;20:1021-8.
50
51
- 52 10. Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra
53
54 AS, Basquill C, Lamb CA, Cameron FL, Murray CD, Parkes M, Gooding I, Ahmad T, Gaya
55
56
57
58
59
60

DR, Mann S, Lindsay JO, Gordon J, Satsangi J, Hart A, McCartney S, Irving P; UK Anti-TNF withdrawal study group, Lees CW. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. *Aliment Pharmacol Ther* 2016; doi: 10.1111/apt.13547. Epub ahead of print.

11. Gisbert JP, Alicia C Marín AC, Chaparro M. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. *Am J Gastroenterol* 2016;111:632-47.

12. Torres J, Boyapati RK, Kennedy N, Louis E, Colombel J-F, Satsangi J. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients with Inflammatory Bowel Disease. *Gastroenterology* 2015;149:1716-30.

13. Bortlik M, Duricova D, Machkova N, Bortlik M, Duricova D, Machkova N. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. *Scand J Gastroenterol* 2016;2:196-202.

14. Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. *Clin Gastroenterol Hepatol* 2014;12:1474–81.

15. Rismo R, Olsen T, Cui G, Paulssen EJ, Christiansen I, Johnsen K, Florholmen J, Goll R. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease. *Scand J Gastroenterol* 2013;48:311-9.

16. Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission. *Clin Gastroenterol Hepatol* 2015;13:1103-10.

17. Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC, Millan M, Bailey R, Todoruk D, Cherry R, Teshima CW, Dieleman L, Fedorak RN. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. *Aliment Pharmacol Ther* 2010;32:1129–34.
18. De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. Postoperative recurrent luminal Crohn's disease: a systematic review. *Inflamm Bowel Dis* 2012;18(4):758-77.
19. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. *Gastrointest Endosc* 2004;60:505–12.
20. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. *N Engl J Med* 1987;317:1625–9.
21. Moskovitz DN, Daperno M, Van Assche G. Defining and validating cut-offs for the Simple Endoscopic Score for Crohn's Disease. *Gastroenterology* 2007;132:S1097.
22. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. *Gastroenterology* 2007;132: 763–86.
23. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijis I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. *Inflamm Bowel Dis* 2009;15:1295–1301.
24. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP; European Crohn's and Colitis Organisation

(ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. *J Crohns Colitis* 2010;4:28-62.

25. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quarry A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? *Am J Gastroenterol* 2011;106:199–21.

26. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. *Inflamm Bowel Dis* 2011;17:1415-22.

27. Reenaers C, Nachury M, Bouhnik Y, Laharie D, Allez M, Dupas JL, Amiot A, Savoye G, Altwegg R, Devos M, Malamut G, Bourreille A, Flourie B, Marteau P, Vuitton L, Coffin B, Viennot S, Colombel JF, Mary JY, Louis E, on behalf of GETAID . Long-term outcome after infliximab withdrawal for sustained remission in Crohn's disease. *UEG Journal* 2015; October 2015; 3 (5 suppl) A31.

28. Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. *Aliment Pharmacol Ther* 2014;40:338–53.

29. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, Khawaja SA, Bagnall

R, Burke DA, Todhunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell DP, Satsangi J, Mansfield JC; Wellcome Trust Case Control Consortium, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. *Nat Genet* 2007;39:830–2.

30. Arijis I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. *Gut* 2009;58:1612–9.

31. Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn's disease. *Inflamm Bowel Dis* 2011;17:2366–91.

32. Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A; EPACT-II Update Panellists. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. *J Crohns Colitis* 2013;7:820–6.

33. Farrell RJ, Alsahli L, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Hydrocortisone intravenous premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. *Gastroenterology* 2003;124:917–24.

34. Steenholdt C, Svenson M, Bendtzen K, Thomsen O. Ø, Brynskov J, Ainsworth M. A. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2011;34: 51–8.

35. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. *Scand J Gastroenterol* 2004;39:1017–20.

A.

B.

ADA; anti-drug antibody

Table 1. Patients' clinical and demographic characteristics at baseline.

	Ulcerative colitis/ Inflammatory bowel disease unclassified n= 34	Crohn's disease n= 17
Male/Female	19/15	8/9
Age at onset (median, range)	26 (8-45)	23 (13-42)
Age at induction (median, range)	32 (13-58)	33 (15-52)
Active smoker, n (%)	4 (12)	4 (24)
Disease duration (median, range)	6 (1-35)	10 (3-26)
Previous bowel surgery, n (%)		8 (47)
Disease behavior (Mb Crohn), n (%)		
Inflammatory (B1)		11 (65)
Stricturing (B2)		4 (24)
Penetrating (B3)		1 (6)
B1 ± perianal disease		0
B2 ± perianal disease		1 (6)
B3 ± perianal disease		0
Disease location	Proctitis 0 Left colon 14 Extensive colitis 20	Ileum (L1) 1 Colon (L2) 4 Ileocolon (L3) 12
Concomitant medications, n (%)		
No concomitant medications		1 (6)
Mesalazine	1 (3)	3 (18)
Azathioprine/6-MP	4 (12)	7 (41)
Azathioprine/6-MP+ mesalazine	12 (35)	5 (29)
Methotrexate + mesalazine	17 (50)	1 (6)
Duration of TNFα-blocking therapy prior to cessation of therapy (months)		
Infliximab (median, range)	14 (11-78)	32 (11-72)
Adalimumab (median, range)		26 (16-36)
TNFα-blocking therapy, n (%)		
Infliximab	34 (100)	12 (71)
Adalimumab		5 (29)

6-MP = 6-Mercaptopurine

Table 2. Predictors for disease relapse in the study population.

Variable	P- value	Hazard Ratio	95% CI lower	upper
Diagnosis; CD versus UC/IBDU	0.919	1.042	0.469	2.316
Male sex	0.780	0.899	0.425	1.899
Age at diagnosis	0.341	0.977	0.931	1.025
Age at diagnosis; <25 y versus ≥25 y	0.073	0.492	0.227	0.069
Age at diagnosis; < 20 y versus ≥ 20 y	0.090	0.508	0.232	1.112
Localisation of CU	0.280	1.704	0.648	4.483
Localisation of CD	0.345	1.000		
L3 versus L1	0.243	3.888	0.398	38.017
L3 versus L2	0.464	0.453	0.054	3.778
Disease behavior (CD)	0.995	1.000		
B1 versus B2	0.793	0.802	0.154	4.177
B1 versus B3	0.995	1.008	0.107	9.470
B1 versus B2 + perianal disease	0.242	2.391	0.555	10.298
Smoking	0.252	1.000		
No versus <10 cigarretts / day	0.125	0.383	0.112	1.306
No versus smoker	0.356	0.644	0.253	1.640
No versus smoker or previous smoker	0.117	0.524	0.233	1.177
Age at induction	0.375	0.981	0.941	1.023
Age at induction; < 30 versus ≥ 30 - 40	0.361	0.662	0.273	1.605
Age at induction; < 30 versus ≥ 41	0.927	0.956	0.362	2.526
Duration of the disease at induction	0.974	1.001	0.949	1.055
Duration of the disease; > 5 - 10 years	0.173	1.876	0.760	4.630
Duration of the disease; ≥ 11 years	0.447	1.451	0.556	3.784
Previous surgery	0.577	0.739	0.255	2.140
Positive family history	0.791	0.876	0.331	2.324
TNF α-blocking therapy used; IFX vs. ADA	0.573	1.418	0.421	4.782
Duration of the TNFα-blocking therapy; median	0.995	1.000	0.977	1.024
CRP at discontinuation; median	0.450	0.935	0.785	1.113
Hemoglobin at discontinuation; median	0.434	1.010	0.985	1.036

CD = Crohn's Disease; UC = Ulcerative Colitis; IBDU = Inflammatory Bowel Disease type Unclassified; TNF = Tumour Necrosis Factor; IFX = Infliximab; ADA = Adalimumab; CRP = C-reactive protein